Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shanghai Xunyao Biotechnology

Request full access

A cutting-edge medication development company focused on coagulation and fibrosis

ChinaFounded 2021Biotech & Life Sciences

About Shanghai Xunyao Biotechnology

Established in 2021, Shanghai Xunyao Biotechnology Co., Ltd. (also known as Synvida-Bio) is a biopharmaceutical company that emerged from a strategic, mixed-ownership collaboration. The company was founded by Professor Junling Liu and his research group from the School of Medicine at Shanghai Jiao Tong University, in partnership with Shanghai Pharmaceuticals Holding Co., Ltd. This structure combines academic research with industrial and capital resources, aiming to accelerate drug development.

The firm's core business is the research and development of innovative therapeutics for unmet clinical needs, with a particular focus on blood-related disorders. Its technology platform, which integrates synthetic biology with AI, is dedicated to the discovery and modification of antibody and protein drugs. The company's pipeline targets a range of diseases including hemophilia, thrombocytopenia, pulmonary fibrosis, and various thrombotic diseases. Beyond this, Synvida-Bio is also engaged in developing nucleic acid therapies and cell-based treatments for a broader spectrum of therapeutic areas such as neoplasms, nervous system diseases, and immune system disorders.

Synvida-Bio operates on a model that involves advancing its own drug pipeline and potentially out-licensing its developments to larger pharmaceutical partners for late-stage clinical trials and commercialization. The company's pipeline includes several drug candidates, such as a recombinant humanized anti-PEAR1 monoclonal antibody, with some projects having reached the pre-IND application stage and clinical trials. The company secured $28.1 million in a Series A venture capital round in January 2024, with investors including Lapam Capital and Shanghai Healthcare Capital, to fund its ongoing research and development activities.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
52.0/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model
SaaS
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jan 2024 $28M $110M SHC Shanghai Biomedical Fund · Longpan Investment ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Shanghai Xunyao Biotechnology website traffic

Latest recorded traffic for Shanghai Xunyao Biotechnology is 200 monthly website visits.

Latest monthly visits200
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Shanghai Xunyao Biotechnology in its local ecosystem

Live from Dealroom

The Shanghai Xunyao Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Longpan Investment
  • SHC Shanghai Biomedical Fund
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shanghai Xunyao Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shanghai Xunyao Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.